© 2005 Oxford University Press
ARTICLE |
Bone Turnover Markers as Predictors of Skeletal Complications in Prostate Cancer, Lung Cancer, and Other Solid Tumors
Affiliations of authors: Academic Unit of Clinical Oncology, Cancer Research Centre, Weston Park Hospital, Sheffield, England, United Kingdom (JEB, REC); University of Waterloo, Waterloo, Ontario, Canada (RJC, KAL); Juravinski Cancer Centre, Department of Medical Oncology, McMaster University, Hamilton, Ontario, Canada (PM); Milton S. Hershey Medical Center, Hershey, PA (AL); Centre Hospitalier de l’Université de Montréal, Hôpital Notre-Dame, Montréal, Québec, Canada (FS); Massachusetts General Hospital, Boston, MA (MS); Novartis Pharmaceuticals Corporation, East Hanover, NJ (MZ, YJH)
Correspondence to: Pierre Major, MD, Juravinski Cancer Centre, 699 Concession St., Hamilton, ON L8V 5C2, Canada (e-mail: pierre.major{at}hrcc.on.ca)
Background: Whether bone markers have prognostic value in patients with bone metastases is unknown. We investigated this question in patients with bone metastases secondary to prostate cancer and to non–small-cell lung cancer (NSCLC) and other solid tumors assigned to the placebo arms of two phase III trials of zoledronic acid. Methods: Levels of the urinary bone resorption marker N-telopeptide and the serum bone formation marker bone-specific alkaline phosphatase were assessed every 3 months for patients with prostate cancer (n = 203) or NSCLC or other solid tumors (n = 238) and were categorized as low or high. Patients were monitored for skeletal-related events, bone disease progression, and death. The relative risks (RRs) and 95% confidence intervals (CIs) for these outcomes were estimated for patients with high versus low levels of each marker using intensity-based multiple event and Cox regression models. All statistical tests were two-sided. Results: In each disease group and overall, high levels of each marker at the beginning of the study were statistically significantly associated with an increased risk of negative outcomes. Use of recent marker assessments as time-dependent covariates gave even greater prognostic significance. High N-telopeptide levels were a stronger prognostic indicator of negative outcomes than bone-specific alkaline phosphatase levels. In recent assessments, patients with high N-telopeptide levels had an increased relative risk of skeletal-related events (prostate cancer, RR = 3.25, 95% CI = 2.26 to 4.68, P<.001; NSCLC and other solid tumors, RR = 1.79, 95% CI = 1.15 to 2.79, P = .010), disease progression (prostate cancer, RR = 2.02, 95% CI = 1.48 to 2.74, P<.001; NSCLC and other solid tumors, RR = 1.91, 95% CI = 1.16 to 3.15, P = .011), and death (prostate cancer, RR = 4.59, 95% CI = 2.82 to 7.46, P<.001; NSCLC and other solid tumors, RR = 2.67, 95% CI = 1.85 to 3.85, P<.001) compared with patients with low N-telopeptide levels. Conclusions: Baseline and recent bone marker levels were predictive of negative clinical outcomes in patients with bone metastases secondary to prostate cancer and to NSCLC and other solid tumors. N-telopeptide levels were more consistent prognostic indicators than bone-specific alkaline phosphatase for all tumor types, reflecting the key role of osteolysis in the development of skeletal complications.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  R. E. Miller, M. Roudier, J. Jones, A. Armstrong, J. Canon, and W. C. Dougall RANK ligand inhibition plus docetaxel improves survival and reduces tumor burden in a murine model of prostate cancer bone metastasis Mol. Cancer Ther., July 1, 2008; 7(7): 2160 - 2169. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. R. Nair, H. Avila, X. Ma, Z. Wang, M. Lennartz, B. G. Darnay, D. D. Boyd, and C. Yan A Novel High-Throughput Screening System Identifies a Small Molecule Repressive for Matrix Metalloproteinase-9 Expression Mol. Pharmacol., March 1, 2008; 73(3): 919 - 929. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Zheng, H. Zhou, J. R.K. Modzelewski, R. Kalak, J. M. Blair, M. J. Seibel, and C. R. Dunstan Accelerated Bone Resorption, Due to Dietary Calcium Deficiency, Promotes Breast Cancer Tumor Growth in Bone Cancer Res., October 1, 2007; 67(19): 9542 - 9548. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Lipton, G. G. Steger, J. Figueroa, C. Alvarado, P. Solal-Celigny, J.-J. Body, R. de Boer, R. Berardi, P. Gascon, K. S. Tonkin, et al. Randomized Active-Controlled Phase II Study of Denosumab Efficacy and Safety in Patients With Breast Cancer-Related Bone Metastases J. Clin. Oncol., October 1, 2007; 25(28): 4431 - 4437. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Lipton, R. J. Cook, P. Major, M. R. Smith, and R. E. Coleman Zoledronic Acid and Survival in Breast Cancer Patients with Bone Metastases and Elevated Markers of Osteoclast Activity Oncologist, September 1, 2007; 12(9): 1035 - 1043. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J-J Body, M Lichinitser, S Tjulandin, P Garnero, and B Bergstrom Oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases Ann. Onc., July 1, 2007; 18(7): 1165 - 1171. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. Kyle, G. C. Yee, M. R. Somerfield, P. J. Flynn, S. Halabi, S. Jagannath, R. Z. Orlowski, D. G. Roodman, P. Twilde, and K. Anderson American Society of Clinical Oncology 2007 Clinical Practice Guideline Update on the Role of Bisphosphonates in Multiple Myeloma J. Clin. Oncol., June 10, 2007; 25(17): 2464 - 2472. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. O. Lewis What's New in Musculoskeletal Oncology J. Bone Joint Surg. Am., June 1, 2007; 89(6): 1399 - 1407. [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Johansen, K. Brasso, P. Iversen, B. Teisner, P. Garnero, P. A. Price, and I. J. Christensen Changes of Biochemical Markers of Bone Turnover and YKL-40 Following Hormonal Treatment for Metastatic Prostate Cancer Are Related to Survival Clin. Cancer Res., June 1, 2007; 13(11): 3244 - 3249. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Lu, Z. Cai, G. Xiao, E. T. Keller, A. Mizokami, Z. Yao, G. D. Roodman, and J. Zhang Monocyte Chemotactic Protein-1 Mediates Prostate Cancer-Induced Bone Resorption Cancer Res., April 15, 2007; 67(8): 3646 - 3653. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. A. Guise Bone Loss and Fracture Risk Associated with Cancer Therapy Oncologist, November 1, 2006; 11(10): 1121 - 1131. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. A. Guise, K. S. Mohammad, G. Clines, E. G. Stebbins, D. H. Wong, L. S. Higgins, R. Vessella, E. Corey, S. Padalecki, L. Suva, et al. Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin. Cancer Res., October 15, 2006; 12(20): 6213s - 6216s. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. E. Coleman Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin. Cancer Res., October 15, 2006; 12(20): 6243s - 6249s. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. L. Vessella and E. Corey Targeting factors involved in bone remodeling as treatment strategies in prostate cancer bone metastasis. Clin. Cancer Res., October 15, 2006; 12(20): 6285s - 6290s. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. R. Smith Bisphosphonates for Metastatic Bone Disease -- Too Much of a Good Thing? IBMS BoneKEy, September 1, 2006; 3(9): 24 - 27. [Full Text] [PDF]
|
|
|
|
|
|
D. Cameron, M. Fallon, and I. Diel Ibandronate: Its Role in Metastatic Breast Cancer Oncologist, September 1, 2006; 11(suppl_1): 27 - 33. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Cook, R. Coleman, J. Brown, A. Lipton, P. Major, Y. J. Hei, F. Saad, and M. R. Smith Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer. Clin. Cancer Res., June 1, 2006; 12(11): 3361 - 3367. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. N. Lara Jr., W. M. Stadler, J. Longmate, D. I. Quinn, J. Wexler, M. Van Loan, P. Twardowski, P. H. Gumerlock, N. J. Vogelzang, E. E. Vokes, et al. A Randomized Phase II Trial of the Matrix Metalloproteinase Inhibitor BMS-275291 in Hormone-Refractory Prostate Cancer Patients with Bone Metastases Clin. Cancer Res., March 1, 2006; 12(5): 1556 - 1563. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-J. Body, T. Facon, R. E. Coleman, A. Lipton, F. Geurs, M. Fan, D. Holloway, M. C. Peterson, and P. J. Bekker A Study of the Biological Receptor Activator of Nuclear Factor-{kappa}B Ligand Inhibitor, Denosumab, in Patients with Multiple Myeloma or Bone Metastases from Breast Cancer Clin. Cancer Res., February 15, 2006; 12(4): 1221 - 1228. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Leeming, M. Koizumi, I. Byrjalsen, B. Li, P. Qvist, and L. B. Tanko The Relative Use of Eight Collagenous and Noncollagenous Markers for Diagnosis of Skeletal Metastases in Breast, Prostate, or Lung Cancer Patients Cancer Epidemiol. Biomarkers Prev., January 1, 2006; 15(1): 32 - 38. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Lipton, R. E. Coleman, P. Major, J. E. Brown, K.-A. Lee, M. Smith, F. Saad, Y. Chen, Y. Jiang, and R. Cook Baseline N-Telopeptide Levels Correlate with Risk of Skeletal Morbidity in Patients with Multiple Myeloma during Zoledronic Acid Therapy. Blood (ASH Annual Meeting Abstracts), November 16, 2005; 106(11): 3456 - 3456. [Abstract]
|
|
|
|
|
|
M. D. Michaelson and M. R. Smith Bisphosphonates for Treatment and Prevention of Bone Metastases J. Clin. Oncol., November 10, 2005; 23(32): 8219 - 8224. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Bell Efficacy of Ibandronate in Metastatic Bone Disease: Review of Clinical Data Oncologist, October 1, 2005; 10(suppl_1): 8 - 13. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. van der Pluijm, I. Que, B. Sijmons, J. T. Buijs, C. W.G.M. Lowik, A. Wetterwald, G. N. Thalmann, S. E. Papapoulos, and M. G. Cecchini Interference with the Microenvironmental Support Impairs the De novo Formation of Bone Metastases In vivo Cancer Res., September 1, 2005; 65(17): 7682 - 7690. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. E. Coleman, P. Major, A. Lipton, J. E. Brown, K.-A. Lee, M. Smith, F. Saad, M. Zheng, Y. J. Hei, J. Seaman, et al. Predictive Value of Bone Resorption and Formation Markers in Cancer Patients With Bone Metastases Receiving the Bisphosphonate Zoledronic Acid J. Clin. Oncol., August 1, 2005; 23(22): 4925 - 4935. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. D. Roodman High Bone Turnover Markers Predict Poor Outcome in Patients With Bone Metastasis J. Clin. Oncol., August 1, 2005; 23(22): 4821 - 4822. [Full Text] [PDF]
|
|
|
|
|
|
R. E. Coleman Bisphosphonates in breast cancer Ann. Onc., May 1, 2005; 16(5): 687 - 695. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. C Gainford, G. Dranitsaris, and M. Clemons Recent developments in bisphosphonates for patients with metastatic breast cancer BMJ, April 2, 2005; 330(7494): 769 - 773. [Full Text] [PDF]
|
|